Knockdown of DNA/RNA‑binding protein KIN17 promotes apoptosis of triple‑negative breast cancer cells

Gao,Xiang; Liu,Zhenping; Zhong,Meifeng; Wu,Kunhe; Zhang,Yuzhao; Wang,Hongmei; Zeng,Tao

doi:10.3892/ol.2018.9597

Knockdown of DNA/RNA‑binding protein KIN17 promotes apoptosis of triple‑negative breast cancer cells

Authors:
- Xiang Gao
- Zhenping Liu
- Meifeng Zhong
- Kunhe Wu
- Yuzhao Zhang
- Hongmei Wang
- Tao Zeng
View Affiliations

Affiliations: Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Laboratory Medicine, The People's Hospital of Shajing, Shenzhen, Guangdong 518104, P.R. China, Department of Pathology, Guangdong Women and Children's Hospital, Guangzhou, Guangdong 511400, P.R. China, Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: October 18, 2018 https://doi.org/10.3892/ol.2018.9597
Pages: 288-293
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effective therapy for breast cancer has been extensively studied worldwide, particularly for triple‑negative breast cancer and drug‑resistant subtypes. DNA/RNA‑binding protein KIN17 (kin17) has been reported to be significantly upregulated in breast cancer cells, and is proposed to serve a role in the regulation of cell proliferation. The present study further investigated the association of kin17‑knockdown with breast cancer cell apoptosis. Cell Counting kit‑8, flow cytometry, TUNEL assay and caspase 3/7 analysis were performed on MDA‑MB‑231 cells to determine the association between kin17 and breast cancer cell apoptosis. In addition, western blot analysis was performed to investigate the mechanism of kin17 in the apoptosis of MDA‑MB‑231 cells. The results revealed that knockdown of kin17 inhibited proliferation and promoted apoptosis of MDA‑MB‑231 cells, and suggested a poly (adenosine diphosphate‑ribose) polymerase‑related mechanism behind the apoptosis of the cells. These findings suggested that kin17 could become a novel target for breast cancer therapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Jensen MB, Ejlertsen B, Mouridsen HT and Christiansen P; Danish Breast Cancer Cooperative Group, . Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2 Suppl 55:S24–S35. 2016. View Article : Google Scholar
3	Lukong KE: Understanding breast cancer – The long and winding road. BBA Clin. 7:64–77. 2017. View Article : Google Scholar : PubMed/NCBI
4	O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M and McCann A: The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 3:257–275. 2015. View Article : Google Scholar : PubMed/NCBI
5	Miah S, Banks CA, Adams MK, Florens L, Lukong KE and Washburn MP: Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. Mol Biosyst. 13:42–55. 2016. View Article : Google Scholar : PubMed/NCBI
6	Denkert C, Liedtke C, Tutt A and von Minckwitz G: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 389:2430–2442. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kannouche P, Mauffrey P, Pinon-Lataillade G, Mattei MG, Sarasin A, Daya-Grosjean L and Angulo JF: Molecular cloning and characterization of the human KIN17 cDNA encoding a component of the UVC response that is conserved among metazoans. Carcinogenesis. 21:1701–1710. 2000. View Article : Google Scholar : PubMed/NCBI
8	Miccoli L, Frouin I, Novac O, Di Paola D, Harper F, Zannis-Hadjopoulos M, Maga G, Biard DS and Angulo JF: The human stress-activated protein kin17 belongs to the multiprotein DNA replication complex and associates in vivo with mammalian replication origins. Mol Cell Biol. 25:3814–3830. 2005. View Article : Google Scholar : PubMed/NCBI
9	Pinon-Lataillade G, Masson C, Bernardino-Sgherri J, Henriot V, Mauffrey P, Frobert Y, Araneda S and Angulo JF: KIN17 encodes an RNA-binding protein and is expressed during mouse spermatogenesis. J Cell Sci. 117:3691–3702. 2004. View Article : Google Scholar : PubMed/NCBI
10	Zeng T, Gao H, Yu P, He H, Ouyang X, Deng L and Zhang Y: Up-regulation of kin17 is essential for proliferation of breast cancer. Plos One. 6:e253432011. View Article : Google Scholar : PubMed/NCBI
11	Yu M, Zhang Z, Yu H, Xue C, Yuan K, Miao M and Shi H: KIN enhances stem cell-like properties to promote chemoresistance in colorectal carcinoma. Biochem Biophys Res Commun. 448:63–69. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Huang S, Gao H, Wu K, Ouyang X, Zhu Z, Yu X and Zeng T: Upregulation of KIN17 is associated with non-small cell lung cancer invasiveness. Oncol Lett. 13:2274–2280. 2017. View Article : Google Scholar : PubMed/NCBI
13	Kou WZ, Xu SL, Wang Y, Wang LW, Wang L, Chai XY and Hua QL: Expression of Kin17 promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo. Oncol Lett. 8:1190–1194. 2014. View Article : Google Scholar : PubMed/NCBI
14	Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al: American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 134:907–922. 2010.PubMed/NCBI
15	Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, et al: Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 107:djv0482015. View Article : Google Scholar : PubMed/NCBI
16	Qiu J, Xue X, Hu C, Xu H, Kou D, Li R and Li M: Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer. 7:167–173. 2016. View Article : Google Scholar : PubMed/NCBI
17	Thornberry NA and Lazebnik Y: Caspases: Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
18	Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 68:383–424. 1999. View Article : Google Scholar : PubMed/NCBI
19	Boccardo F and Rubagotti A: Switching to aromatase inhibitors in early breast cancer. Lancet. 369:533–535. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mirkin S and Pickar JH: Selective estrogen receptor modulators (SERMs): A review of clinical data. Maturitas. 80:52–57. 2015. View Article : Google Scholar : PubMed/NCBI
21	Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A and Esparís-Ogando A: Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One. 4:e55652009. View Article : Google Scholar : PubMed/NCBI
22	Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, Ahel I and Chang P: Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun. 5:44262014. View Article : Google Scholar : PubMed/NCBI
23	Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, et al: Update breast cancer 2017-implementation of novel therapies. Geburtshilfe Frauenheilkd. 77:1281–1290. 2017. View Article : Google Scholar : PubMed/NCBI
24	Okuma HS and Yonemori K: BRCA gene mutations and poly(ADP-Ribose) polymerase inhibitors in triple-negative breast cancer. Adv Exp Med Biol. 1026:271–286. 2017. View Article : Google Scholar : PubMed/NCBI
25	Hamaoka S, Kitazawa N, Nara K, Sasaki A, Kamada A and Okabe T: Selective estrogen receptor modulator. US: pp. 469–476. 2011
26	Jameera Begam A, Jubie S and Nanjan MJ: Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg Chem. 71:257–274. 2017. View Article : Google Scholar : PubMed/NCBI